https://demo1.limegoat.com/hoth-therapeutics-to-attend-ef-hutton-annual-global-conference/ 2024-05-01T17:28:08+00:00 https://demo1.limegoat.com/hoth-therapeutics-to-attend-bio-ceo-and-investor-conference/ 2024-05-02T09:44:46+00:00 https://demo1.limegoat.com/hoth-therapeutics-secures-key-european-regulatory-milestone-with-ema-submission-for-phase-ii-trial-of-ht-001-in-cancer-patients-suffering-from-egfri-induced-skin-toxicities/ 2025-09-10T12:29:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-expands-ht-001-development-with-patent-filings-targeting-drug-induced-hypersensitivity-radiotherapy-induced-rash-and-menin-inhibitor-associated-skin-toxicities/ 2025-09-24T12:13:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-launches-va-backed-study-of-novel-gdnf-weight-loss-therapy-targeting-obesity-and-fatty-liver-disease/ 2025-10-27T11:49:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-to-present-at-noble-capital-markets-21st-annual-emerging-growth-equity-conference-december-2-3-2025/ 2025-12-01T13:03:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-issues-comprehensive-pipeline-update-highlighting-clinical-progress-orphan-designated-ht-kit-advancing-ht-001-phase-2-and-new-gdnf-metabolic-program/ 2025-12-03T19:00:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform/ 2026-01-02T13:13:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-reaches-key-eu-regulatory-inflection-point-advancing-ht-001-oncology-trial-toward-multi-country-site-activation/ 2026-01-15T13:17:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-secures-major-international-patent-milestone-for-ht-kit-cancer-program-strengthening-global-oncology-ip-position/ 2026-01-21T13:13:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-delivers-100-clinical-response-with-50-reduction-in-disease-severity-in-open-label-pk-cohort-of-egfr-treated-cancer-patients/ 2026-01-22T13:13:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-addresses-market-rumor-hoth-holds-no-crypto-currency-assets/ 2026-02-05T13:03:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-announces-groundbreaking-positive-results-hoths-ht-va-gdnf-surpasses-semaglutide-in-weight-loss-glucose-control-and-liver-health-in-obesity-model/ 2026-02-10T13:30:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-receives-u-s-notice-of-allowance-for-novel-exon-skipping-therapy-targeting-allergic-diseases/ 2026-02-12T13:33:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-accelerates-ht-001-trial-enrollment-with-new-clinical-site-as-patient-demand-increases/ 2026-02-24T21:15:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-deploys-openai-api-to-advance-development-of-orphan-ht-kit-oncology-program/ 2026-03-04T13:31:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-reports-positive-female-preclinical-data-showing-ht-va-restores-cholesterol-levels-and-improves-lipid-metabolism-in-masld-model/ 2026-03-10T12:13:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-reports-positive-ht-001-pk-safety-and-clinical-activity-data-in-cancer-patients-with-egfr-therapy-associated-skin-toxicities-showing-77-increase-in-drug-exposure-and-minimal-syste/ 2026-03-24T12:13:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-deploys-openclawtm-ai-platform-to-accelerate-drug-discovery/ 2026-03-26T12:30:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-announces-issuance-of-chinese-patent-for-cancer-cell-targeting-technology/ 2026-03-31T12:07:00+00:00 https://demo1.limegoat.com/hungary-approves-trial-expansion-as-ht-001-meets-primary-endpoint-in-interim-analysis-with-patients-reaching-ariga-1-by-week-six/ 2026-04-01T12:14:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-announces-2-0-million-registered-direct-offering/ 2026-04-01T17:52:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-announces-closing-of-2-0-million-registered-direct-offering/ 2026-04-02T20:05:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-hoth-reports-positive-ht-va-crada-data-gdnf-reprograms-liver-fat-metabolism-shuts-down-fat-creation-gene-and-activates-fat-burning-pathways-outperforming-semaglutide-2/ 2026-04-13T21:23:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-hoth-reports-positive-ht-va-crada-data-gdnf-reprograms-liver-fat-metabolism-shuts-down-fat-creation-gene-and-activates-fat-burning-pathways-outperforming-semaglutide/ 2026-04-14T11:00:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-secures-european-authorization-in-spain-for-ht-001-phase-2a-trial-as-interim-data-show-strong-efficacy-in-cancer-patients/ 2026-05-05T20:17:00+00:00 https://demo1.limegoat.com/ai-chip-energy-efficiency-hoth-therapeutics-restructures-as-rocket-one-inc-to-enter-the-ai-semiconductor-infrastructure-market-with-acquisition-of-exclusive-rights-to-next-generation-ai-semiconducto/ 2026-05-19T12:17:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-awarded-u-s-patent-for-cancer-fighting-ht-kit-oncology-platform/ 2026-05-26T12:18:00+00:00 https://demo1.limegoat.com/hoth-therapeutics-becomes-rocket-one-inc-nasdaq-rkto-targeting-the-space-economy-with-next-generation-nanomagnetic-ai-chip-technology-and-ultra-low-power-radiation-tolerant-computing-for-space-a/ 2026-05-27T12:11:00+00:00 https://demo1.limegoat.com/rocket-one-accepted-into-amd-ai-developer-program-to-advance-simulation-of-next-generation-nanomagnetic-ai-accelerator-architecture-for-ai-defense-and-space-applications/ 2026-05-28T12:19:00+00:00 https://demo1.limegoat.com/rocket-one-appoints-dr-supriyo-bandyopadhyay-as-lead-technical-advisor-of-ai-nanomagnetic-technology/ 2026-06-01T14:18:00+00:00 https://demo1.limegoat.com/rocket-one-appoints-major-general-malcolm-b-frost-ret-to-space-and-defense-advisory-board/ 2026-06-03T12:22:00+00:00